Medifast (NYSE:MED) and Mannatech (NASDAQ:MTEX) Head-To-Head Contrast

Mannatech (NASDAQ:MTEX) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Insider & Institutional Ownership

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 47.5% of Mannatech shares are owned by insiders. Comparatively, 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Mannatech and Medifast, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1	0	0	0	1.00
Medifast	1	2	0	0	1.67

Medifast has a consensus target price of $12.00, indicating a potential upside of 0.00%. Given Medifast’s stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than Mannatech.

Profitability

This table compares Mannatech and Medifast’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	-6.90%	-2,383.34%	-24.43%
Medifast	-8.08%	-6.69%	-5.25%

Earnings and Valuation

This table compares Mannatech and Medifast”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04 million	0.11	-$15.21 million	($3.91)	-1.62
Medifast	$316.93 million	0.42	-$18.67 million	($2.33)	-5.15

Mannatech has higher earnings, but lower revenue than Medifast. Medifast is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Mannatech has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Medifast has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Summary

Medifast beats Mannatech on 8 of the 13 factors compared between the two stocks.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

About Medifast

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.